康华生物（300841）8月15日主力资金净流入5138.92万元

Group 1 - The core viewpoint of the news is that Kanghua Biological (300841) has experienced a significant decline in revenue and net profit in its latest quarterly report, indicating potential challenges for the company moving forward [1] - As of August 15, 2025, Kanghua Biological's stock closed at 92.06 yuan, up 3.67%, with a turnover rate of 5.31% and a trading volume of 63,100 hands, amounting to a transaction value of 574 million yuan [1] - The company reported total operating revenue of 138 million yuan for the first quarter of 2025, a year-on-year decrease of 55.70%, and a net profit attributable to shareholders of 20.71 million yuan, down 86.15% year-on-year [1] Group 2 - Kanghua Biological has a current liquidity ratio of 5.797 and a quick ratio of 5.334, indicating strong short-term financial health, while its debt-to-asset ratio stands at 10.70% [1] - The company has made investments in five enterprises and has participated in 646 bidding projects, showcasing its active engagement in the market [2] - Kanghua Biological holds 67 trademark registrations and 253 patents, along with 402 administrative licenses, reflecting its commitment to intellectual property and regulatory compliance [2]